FRA
AZN icon

Front Row Advisors’s AstraZeneca AZN Stock Holding History

Front Row Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-83
Closed -$12.9K – 533
2024
Q2 		$12.9K Buy
83
+2
+2% +$301 ﹤0.01% 508
2024
Q1 		$10.9K Buy
+81
New +$10.7K ﹤0.01% 560
2023
Q4 		– Sell
-91
Closed -$12.3K – 504
2023
Q3 		$12.3K Buy
91
+6
+7% +$819 0.01% 473
2023
Q2 		$12K Sell
85
-13
-13% -$1.91K 0.01% 475
2023
Q1 		$14K Buy
98
+3
+3% +$404 0.01% 443
2022
Q4 		$13K Sell
95
-29
-23% -$3.64K 0.01% 440
2022
Q3 		$14K Sell
124
-109
-47% -$13.8K 0.01% 440
2022
Q2 		$31K Sell
233
-26
-10% -$3.41K 0.02% 295
2022
Q1 		$34K Buy
259
+3
+1% +$360 0.01% 307
2021
Q4 		$30K Sell
256
-10
-4% -$1.18K 0.01% 337
2021
Q3 		$32K Buy
266
+9
+4% +$1.05K 0.01% 320
2021
Q2 		$30K Buy
257
+114
+80% +$12.5K 0.01% 336
2021
Q1 		$14K Buy
143
+7
+5% +$704 0.01% 472
2020
Q4 		$14K Buy
136
+6
+5% +$636 0.01% 446
2020
Q3 		$14K Buy
130
+77
+145% +$8.56K 0.01% 436
2020
Q2 		$6K Sell
53
-2
-4% -$207 ﹤0.01% 573
2020
Q1 		$6K Sell
55
-4
-7% -$377 ﹤0.01% 562
2019
Q4 		$6K Buy
59
+8
+16% +$753 ﹤0.01% 567
2019
Q3 		$5K Buy
51
+25
+96% +$2.17K ﹤0.01% 580
2019
Q2 		$2K Buy
26
+8
+44% +$627 ﹤0.01% 807
2019
Q1 		$1K Hold
18
– – ﹤0.01% 928
2018
Q4 		$1K Hold
18
– – ﹤0.01% 903
2018
Q3 		$1K Hold
18
– – ﹤0.01% 874
2018
Q2 		$1K Hold
18
– – ﹤0.01% 923
2018
Q1 		$1K Hold
18
– – ﹤0.01% 857
2017
Q4 		$1K Buy
+18
New +$1.21K ﹤0.01% 746

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Front Row Advisors's AZN Position: Q3 2024 in Review

Front Row Advisors sold out of AstraZeneca (AZN) in Q3 2024, closing a stake of 83 shares — an estimated $12.9K sold.

Front Row Advisors first reported a position in AZN in Q4 2017 and held it in 26 quarters. The position peaked at $34K in Q1 2022. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

  • Front Row Advisors reported no remaining AstraZeneca position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 83 AstraZeneca shares in Q3 2024, an estimated $12.9K.
  • Front Row Advisors first reported a position in AstraZeneca in Q4 2017 and held it in 26 quarters.
  • Front Row Advisors's AstraZeneca position peaked at $34K in Q1 2022.
  • 1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.